Cole Werble
The signature event for the Food & Drug Administration during the landmark "drug safety" year of 2007 occurred on July 30 when the head of one of FDA’s drug review offices openly disputed a top drug safety officer at a public advisory
Open Disputes at FDA Advisory Committees: Get Ready for Institutionalized Cacophony
Recent FDA advisory committees on Avandia and Ketek have featured conflicting points of view from FDA internal staff. Get ready for more public airings in the future. Influential Iowa Republican Senator Charles Grassely is directing FDA to bring all opinions into the open.